TABLE 17.4Large Animal Algogenic/Pharmacodynamic Pain Models

SpeciesPain Stimulus/ModelAssessment MethodPharmacology TestedActive?Reference
PrimateInjected capsaicinTail withdrawal latencyFentanyl (0.003–0.1 mg)YKo et al. 1998
DAMGO (0.001–0.03 mg)YKo et al. 1998
PrimateTopical capsaicinTail withdrawal latencyKappa opioid agonist—U69.593 (0.01–0.1 mg/kg)YButelman et al. 2003
Ketamine (0.32–1.8 mg/kg)YButelman et al. 2003
MK-801 (0.032–0.056 mg/kg)YButelman et al. 2003
Gabapentin (50–150 mg/kg)YChoong et al. 2007; see Figure 17.1
PrimateInjected prostaglandin-E2Tail withdrawal latencyMorphine (0.32–3.2 mg/kg)YNegus et al. 1993
BW373U86 (0.18–0.56 mg/kg)NButelman et al. 1995
PrimateInjected bradykininTail withdrawal latencyBW373U86 (0.18–0.56 mg/kg s.c.)YButelman et al. 1995
PrimateTopical capsaicinVasodilationCGRP receptor antagonist BIBN4096BS (0.03 mg/kg)YHershey et al. 2005

From: Chapter 17, Large Animal Models for Pain Therapeutic Development

Cover of Translational Pain Research
Translational Pain Research: From Mouse to Man.
Kruger L, Light AR, editors.
Boca Raton, FL: CRC Press/Taylor & Francis; 2010.
Copyright © 2010 by Taylor and Francis Group, LLC.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.